Impact of new antifungal breakpoints on antifungal resistance in Candida species

Journal of Clinical Microbiology

Volumn 52, Issue 3, 2014, Pages 994-997

  Fothergill, Annette W ^a   Sutton, Deanna A ^a   McCarthy, Dora I ^a   Wiederhold, Nathan P ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DRUG TREATMENT FAILURE; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REFERENCE VALUE; STRAIN DIFFERENCE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84894593134     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03044-13     Document Type: Article

References (19)

1. CLSI. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195. http://dx.doi.org/10.1016/j.drup.2010.09.002.
3. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Susceptibility Testing. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14: 164-176. http://dx.doi.org/10.1016/j.drup.2011.01.004.
4. Pfaller MA. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125:S3-S13. http://dx.doi .org/10.1016/j.amjmed.2011.11.001.
5. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J. Clin. Microbiol. 51:2571-2581. http://dx.doi.org/10.1128/JCM.00308-13.
7. Pfaller MA, Boyken LB, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. 2011. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. J. Clin. Microbiol. 49: 1274-1279. http://dx.doi.org/10.1128/JCM.02437-10.
8. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10 .1093/cid/cit136.
9. Pfaller MA, Diekema DJ, Sheehan DJ. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447. http://dx.doi.org/10. 1128/CMR.19.2.435-447.2006.
10. Cuesta I, Bielza C, Cuenca-Estrella M, Larranaga P, Rodriguez-Tudela JL. 2010. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob. Agents Chemother. 54:1541-1546. http://dx.doi.org/10.1128/AAC.01688-09.
11. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177. http://dx.doi.org/10.1128/AAC.49.8.3171-3177.2005. (Pubitemid 41060556)
12. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, Laguna F, Donnelly JP, Mouton JW, Pahissa A, Cuenca-Estrella M. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51:3599-3604. http://dx.doi.org/10.1128/AAC .00296-07. (Pubitemid 47519349)
13. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. 2006. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44:1740-1743. http://dx.doi.org/10 .1128/JCM.44.5.1740-1743.2006. (Pubitemid 43726263)
14. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. 2004. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42:3137-3141. http://dx.doi.org/10.1128/JCM.42.7.3137-3141.2004. (Pubitemid 38938070)
15. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. 2007. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards instituterecommended broth microdilution methods. J. Clin. Microbiol. 45:70-75. http://dx.doi.org/10.1128/ JCM.01551-06. (Pubitemid 46106408)
16. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. 2008. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J. Clin. Microbiol. 46:551-559. http://dx.doi.org/10.1128/JCM.01952-07. (Pubitemid 351231301)
17. Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. 2013. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J. Clin. Microbiol. 51:2608-2616. http://dx.doi.org/10.1128/JCM.00863-13.
18. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380. http://dx.doi.org/10.1128/JCM.02390-09.
19. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. 2008. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 52:3022-3028. http://dx.doi.org/10.1128/AAC.00116- 08.